Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 23, 1999

View Archived Issues

Chiron files long-term survival data for Proleukin with the FDA

Cell Genesys and EntreMed sign antiangiogenesis gene therapy agreement

Therapeutic Antibodies highlights Q2 1999 developments

Ligand makes significant progress during Q2 1999

Mammaglobin may be a useful marker for breast cancer

MORE study results: raloxifene reduces risk of spinal fracture

Chiron initiates phase III study of Proleukin for HIV

CV Therapeutics reports initial results from ranolazine trial

Stem Cell Sciences and Rhone-Poulenc Rorer enter agreement

WHI-P164, a potential treatment for atherosclerosis in patients with hyperlipidemia, hypertension

FDA approves Aciphex for treatment of GERD and duodenal ulcers

Additional preclinical studies of HE-2000 begin in nonhuman primates

Study commences of pulmonary delivery of migraine therapy

Xoma and Genentech expand hu1124 collaboration to include transplantation

Company Profile: Adherex Technologies

New treatments for alcoholism reported by Lipha

Dual TP antagonist/TxA2 synthase inhibitor presented by Servier

L'Oreal compounds prevent skin aging in experimental models

ICAgen researchers patent new potassium channel blockers

Academic team identifies novel modulators of cholinergic function

Cheil Jedang team synthesizes new oxazolidinones

Preclinical profile of rPSGL-Ig indicates clinical testing is warranted

Phase II results validate Emisphere's technology for oral delivery of heparin

ACS news: Wyeth-Ayerst investigates agents for urinary incontinence

Org-23366: an atypical antipsychotic potentially superior to clozapine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...